About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiology
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
Playback speed
0.5x
0.75x
1x (Normal)
1.25x
1.5x
1.75x
2x
10 seconds
T
Experts Discuss Pros and Cons of Treatment Approaches in PV
By
BMFcases
FEATURING
Taha Bat
,
Ayalew Tefferi
By
BMFcases
FEATURING
Taha Bat
,
Ayalew Tefferi
0 views
May 23, 2024
Comments
0
Login to view comments.
Click here to Login
Featured Video
16:51
Incyte
Effects of PV Treatment on White Blood Cell Count and Thrombotic Risk
Feat.
C. Harrison
Featured Video
01:29
Incyte
Targeting CSF-1R to Manage Inflammation and Fibrosis in GVHD
Recommended
AUTOPLAY
ON
Related
Newest
24:08
Indy Hematology Review
Evaluation, Diagnosis, Prognostication, and Emerging Therapies for M…
Feat.
A. Tefferi
24:35
Indy Hematology Review
Current Approaches in the Treatment of Myeloproliferative Neoplasms
Feat.
A. Tefferi
08:18
Insights from 2023 ASH Annual Meeting
Treatment Strategies for Hematocrit Control in PV
Feat.
A. Zhou
23:35
University of Colorado Division of Hematology
2024 Updates in PV/ET
Feat.
B. McMahon
27:37
Indy Hematology Review
Review of Myeloproliferative Neoplasms
Feat.
A. Tefferi
17:05
BMFcases
Diagnosis and Prognosis in PV: Utility of BM Biopsy, Clinical Findin…
Feat.
T. Bat,
A. Tefferi
10:02
Insights from 2023 ASH Annual Meeting
ASH 2023 Summary: "The Best of MPNs - Highlights & Key Take…
Feat.
R. Mesa
21:52
Insights from 2023 ASH Annual Meeting
ASH 2023 Summary: "MF, ET, and PV - Highlights and Clinical Imp…
Feat.
D. Tremblay
05:20
Prithviraj Bose
When to Switch From Hydroxyurea to Ruxolitinib in PV
08:11
Krisstina Gowin
Counseling Patients With Newly Diagnosed PV or ET
09:27
ASH 2022 Conference Coverage
MAJIC-PV Trial: Ruxolitinib vs. Best Available Therapy for PV Intole…
Feat.
M. McMullin
16:25
Northwestern Medicine Oncology and Hematology
Diagnosis and Goals of Therapy in PV
Feat.
B. Stein
08:44
Krisstina Gowin
Management of Aquagenic Pruritis in Polycythemia Vera
19:47
Monia Marchetti
CYTO-PV Study: Importance of Hematocrit Control and Early Interventi…
17:51
Penn Medicine Cellicon Valley '23: The Future of Cell and Gene Therapies
Chronic GVHD: A Case-Based Discussion
Feat.
L. Perry
16:26
Incyte
Effects of a Treatment Option on Hematocrit Control and Spleen Volum…
Feat.
C. Harrison
51:20
Jerry Spivak
Polycythemia Vera: Disease Overview, Treatment Landscape, and Curren…
27:47
City of Hope
Chronic GVHD: Review Advances in Prevention, Novel Endpoints, and Ta…
Feat.
I. Amanam
16:52
Winship Cancer Institute - Emory University
Updates on Myeloproliferative Neoplasms Including CML
Feat.
A. Hunter
08:49
BMFcases
Experts Address Clinical Questions in PV: Utility of Aspirin, Rusfer…
Feat.
T. Bat,
A. Tefferi
